Article

Neutralization Of SARS-CoV-2 Variants By A Human Polyclonal Antibody Therapeutic (COVID-HIG, NP-028) With High Neutralizing Titers To SARS-CoV-2

2022-02-09

Abstract excerpt

Since the start of the COVID-19 outbreak the World Health Organization (WHO) has classified multiple SARS-CoV-2 Variants-of-Concern and Variants-of-Interest (VOC/VOI) with mutations in their Spike protein that increase transmissibility and/or reduce the effectiveness of vaccines and monoclonal antibody therapeutics. The emergence of these variants represents a significant health risk and highlights the need for ad...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c1f38cb2-a05c-5db1-afdd-7dc2dcbc4758
DOI: 10.1101/2022.01.27.478053

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neutralization Of SARS-CoV-2 Variants By A Human Polyclonal Antibody Therapeutic (COVID-HIG, NP-028) With High Neutralizing Titers To SARS-CoV-2DOI 10.1101/2022.01.27.478053Read

Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19Semantic proximity Read

Epitope Diversity and SARS-CoV-2 Variants Neutralizing Capacity of SARS-CoV-2 Hyperimmune Intravenous Immunoglobulins for Treatment of COVID-19Semantic proximity Read

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variantsSemantic proximity Read

Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concernSemantic proximity Read

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2Semantic proximity Read

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read

Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron)Semantic proximity Read

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its baseSemantic proximity Read

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.Semantic proximity Read

SARS-CoV-2 Infections in mRNA Vaccinated Individuals are Biased for Viruses Encoding Spike E484K and Associated with Reduced Infectious Virus Loads that Correlate with Respiratory Antiviral IgG levelsSemantic proximity Read

Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021–June 2022Semantic proximity Read

Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineagesSemantic proximity Read